Zynerba Pharmaceuticals (ZYNE) Covered Calls

You can sell covered calls on Zynerba Pharmaceuticals to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for ZYNE (prices last updated Mon 4:16 PM ET):

Zynerba Pharmaceuticals (ZYNE) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
12.16 +1.36 12.00 12.19 2.5M -1.3 0.2B
Covered Calls For Zynerba Pharmaceuticals (ZYNE)
Expiration Strike Call Bid Net Debit Return
If Flat
Return If Flat
Aug 16 12.5 1.05 11.14 9.4% 132%
Nov 15 12.5 2.15 10.04 21.4% 66.8%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.